K954607 is an FDA 510(k) clearance for the RETICULOCYTE METHOD. Classified as Counter, Cell, Automated (particle Counter) (product code GKL), Class II - Special Controls.
Submitted by Bayer Corp. (Tarrytown, US). The FDA issued a Cleared decision on August 30, 1996 after a review of 331 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.5200 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.
View all Bayer Corp. devices